Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenprocoumon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 3/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 9/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | ALB | P02768 | 1/20 | 0.73 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | NQO1 | P15559 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenprocoumon SCHEMBL24500477 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| Phenprocoumon SCHEMBL43031 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| Phenprocoumon SCHEMBL24500472 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL7351110 | 0.93 | CYP2C9 (0.87) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL8042698 | 0.92 | CYP2C9 (0.86) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| Warfarin SCHEMBL13724154 | 0.91 | CYP2C9 (0.90) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL7406235 | 0.91 | CYP2C9 (0.82) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL7350773 | 0.91 | CYP2C9 (0.82) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL8868104 | 0.91 | CYP2C9 (0.82) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL7348669 | 0.90 | CYP2C9 (0.81) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112469402-B | Orally administrable and sustained release pharmaceutical dosage forms | 拜耳公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11975107-B2 | Compositions and resulting hard capsules comprising hydrophilic coloring foodstuff concentrates | CAPSUGEL BELGIUM NV (BE) | 2024-05-07 | — | — | US | disclosed |
| CN-117460823-A | Method for separating plasminogen from plasma fraction | 先觉药业咨询公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3826627-B1 | ORALLY ADMINISTERABLE PHARMACEUTICAL DOSAGE FORM WITH MODIFIED RELEASE | BAYER AG (DE) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023081804-A1 | PLATELET DERIVATIVE COMPOSITIONS, AND METHODS OF MAKING AND USING SUCH COMPOSITIONS | CELLPHIRE, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220339113-A1 | COMPOSITIONS AND RESULTING HARD CAPSULES COMPRISING HYDROPHILIC COLORING FOODSTUFF CONCENTRATES | CAPSUGEL BELGIUM NV (BE) | 2022-10-27 | — | — | US | disclosed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| US-20220257547-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-18 | — | — | US | disclosed |
| US-11406601-B2 | Compositions and resulting hard capsules comprising hydrophilic coloring foodstuff concentrates | CAPSUGEL BELGIUM NV (BE) | 2022-08-09 | — | — | US | disclosed |
| US-11344519-B2 | Orally administrable modified-release pharmaceutical dosage form | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257547-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM | GLS, FABP3, TNNC1 | VKORC1 849/4885CYP2C9 132/4885HSD17B10 1400/4885 |
| US-11344519-B2 | Orally administrable modified-release pharmaceutical dosage form | GLS, FABP3, TNNC1 | VKORC1 849/4885CYP2C9 132/4885HSD17B10 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.